Building on these secondary endpoint results, Cadrenal has been granted an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to align on a Phase 3 registration path. The ...
The 2026 AHA/ACC guidelines introduce a five-tier Acute PE Clinical Category system to stratify severity and guide treatment decisions. Mechanical thrombectomy receives a Class 2a recommendation for ...
CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the ...
Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses and patients. By Jan Hoffman President Trump on Thursday ordered cannabis to ...
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical ...
PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of ...
Inhaled heparin significantly lowers the risk of death and ventilation in COVID-19 patients while also showing potential against other respiratory infections. With its unique triple-action benefits, ...
Primary immunodeficiency disorders (PIDs) are a heterogeneous group of disorders characterized, as the name suggests, by deficiencies (abnormal, poor or absent function) in the immune system. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results